What If Washington Declared That:
YOUR Money ISN'T Actually Yours?

Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property.

What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.

• Your savings? At risk.
• Your retirement? Up for grabs.
• Your financial future? Under their control.

This isn't just some legal theory. It's happening right now.

But you don't have to be their next target.

Smart Americans are already making moves to keep their wealth out of Washington's reach—before the next financial lockdown.

We put together a Brand New Wealth Defense Guide that reveals 3 powerful strategies to shield your savings before it's too late.

Get your free guide now by clicking here >>

Because once the trap snaps shut, it'll be too late to escape.

Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech

Author: Jeffrey Neal Johnson. First Published: 8/26/2026.

The wearable technology space is quietly undergoing a structural shift. Forecasts project that the global wearables market will surpass $100 billion in 2026 and reach roughly $230 billion by 2033. Investors seeking the next wave of hardware capitalization are closely watching Oura Health.

Oura is reportedly preparing to seek up to $3 billion in a U.S. public offering at a valuation approaching $16 billion. This potential debut could provide an important price-discovery mechanism for pure-play wearable health data platforms.

Most Interesting Gold Stories Rarely Start Where Everyone Is Looking (Ad)

A small explorer is working in a frontier gold-copper region near a proven multi-billion-dollar producer.

The company holds a large land package, high-grade surface samples, and now has a second drill turning.

Most investors wait for confirmation. This is the stage before that happens.

Look closer at the story before it becomes obvious to everyone else

Rather than being just another tech IPO, Oura's targeted pricing could challenge Wall Street's valuation of established health-tracking platforms. By isolating the premium associated with health data aggregation and recurring subscriptions, the offering could prompt investors to reassess the value of wearable divisions within legacy tech giants.

Moving Beyond Basic Hardware Margins

Oura's potential $16 billion-plus valuation does not emerge in a vacuum. Oura Health is projected to reach approximately $2 billion in sales in 2026, implying an estimated 8x forward revenue multiple at a $16 billion valuation. In the hardware space, achieving that kind of multiple requires more than moving physical units through a supply chain. It relies heavily on high-margin, recurring software subscriptions closely paired with physical devices.

A standalone hardware business traditionally trades at a steep discount because of manufacturing costs, supply chain vulnerabilities and margin compression. Oura operates differently by positioning itself as a pure-play health platform. Users pay upfront for the physical ring, but the value proposition extends to ongoing data processing, sleep tracking and personalized biometric insights delivered through its monthly subscription.

By converting a one-time hardware purchase into a recurring revenue stream, pure-play trackers can create more predictable revenue and improve the economics of the hardware relationship over time. This predictable cash flow can also make the model more attractive to institutional buyers. If institutional markets validate Oura's proposed premium, the offering could establish a distinct benchmark and suggest that investors are willing to assign software-like multiples to hardware companies when their underlying health data ecosystems are robust enough to generate recurring revenue.

Heavyweights in the Corner: Obscured Value in Big Tech Wearables

This pricing event creates an interesting dynamic for established tech ecosystems. Currently, technology sector companies such as Apple Inc. (NASDAQ: AAPL) and Alphabet Inc. (NASDAQ: GOOGL) compete in wearables through products including the Apple Watch, Pixel Watch and Fitbit.

Consider Apple's recent performance. Apple's Wearables, Home and Accessories segment posted approximately $7.88 billion in fiscal Q3 2026, representing a solid 6.5% year-over-year increase. Despite generating billions in revenue, Apple does not report Apple Watch sales separately, making it difficult to isolate the value of the wearable business from the broader category.

Because the Apple Watch primarily serves as an ecosystem anchor designed to keep users connected to the iPhone, iCloud and Apple Fitness+, Wall Street rarely assigns it a standalone multiple. The true value of the wearable is obscured by its role as a supplementary driver of high-margin services.

Alphabet faces a similar structural dynamic. The company recently rolled out its screenless Fitbit Air alongside the Pixel Watch 5, further integrating the Fitbit brand into the Google Health ecosystem. Fitbit Air also puts Google more directly into the growing market for screenless health trackers occupied by companies such as Oura and Whoop. However, Alphabet does not separately disclose the financial contribution of its health-tracking products from its broader hardware operations.

For both Apple and Alphabet, wearables remain relatively small pieces of much larger businesses. Apple's valuation is driven heavily by the iPhone ecosystem and Services, while Alphabet's rests largely on advertising, cloud computing and its growing AI opportunity. As a result, the value of wearables can remain obscured within their broader corporate structures.

Institutional Capital Steps Into the Ring

Institutional capital remains heavily concentrated in diversified technology companies, largely influenced by the ongoing generative AI boom. Alphabet's recent multibillion-dollar custom AI chip deal with Marvell and Apple's reported $1 billion annual outlay for Alphabet's Gemini AI underscore a strategic pivot toward computing power.

Berkshire Hathaway recently boosted its Alphabet stake by 83% to nearly $37.8 billion while retaining a substantial position in Apple. Insiders at both Apple and Alphabet have also recorded recent share sales.

The upcoming Oura IPO will test whether institutional liquidity is prepared to support a targeted wearable hardware pure-play. If Oura successfully secures its $3 billion offering at a targeted valuation of more than $16 billion, it will send a meaningful signal that institutional investors have an appetite for specialized health data platforms.

This dynamic creates a compelling narrative for the physical economy of tech. While software and language models dominate headlines, the actual collection of biological data requires physical hardware. Companies that can bridge the gap between physical data collection and recurring software revenue may be better positioned to command premium multiples.

Such a scenario could put pressure on Apple and Alphabet. When a pure-play competitor achieves a high valuation multiple, investors naturally begin to ask what a legacy tech company's internal division would be worth on the open market. While a spinoff of the Apple Watch or Google Pixel Watch is highly unlikely given their tight integration with broader operating systems, Oura's valuation could give analysts another reference point for assessing the embedded value of these businesses.

The Next Era of Health Tracking

The wearable tech sector is entering a mature phase in which health data aggregation commands a significant premium over basic step tracking. Oura Health's aggressive capitalization strategy highlights the immense value locked inside these data-driven platforms. While Apple and Alphabet continue to lead by sheer volume, their sprawling business models obscure the true multiple their wearable divisions could command independently.

As the wearables market scales past the $100 billion mark this year, the focus will increasingly shift toward margin expansion through subscription software and pure-play health metrics. The potential Oura IPO provides a useful lens for pricing this industry shift and testing how much public-market investors are willing to pay for a standalone wearable health platform.

Investors navigating this space may want to add Oura to their IPO watchlists to gauge broader market sentiment for health hardware. At the same time, those with long-term exposure to Apple or Alphabet could monitor how these tech giants evolve their wearable products and services as specialized competitors attract higher valuations.

Enova’s Earnings Surge Meets a Valuation Test

Authored by Peter Frank. Posted: 9/3/2026.

Enova International (NYSE: ENVA) has been one of the top-performing financial stocks of the past year.

Through brands like CashNetUSA, NetCredit, OnDeck, Headway Capital, Simplic and Pangea, Enova lends to consumers and small businesses that traditional banks often turn away. That has been the source of its strength—and, more recently, some unwanted attention.

The $15 Gold Fund That Pays Up to $1,152/Month (Ad)

Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.

Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.

Discover the gold income fund before the next payout date

The company is also in the middle of the biggest deal in its history: a pending agreement to acquire Grasshopper Bancorp and give itself an actual bank charter.

Combining its lending business, the pending transaction and a long string of earnings beats, Enova is a financial growth stock that analysts rate as a solid Buy.

Earnings Growth Accelerates

The second quarter continued that trend. Revenue for the three months rose 21.6% year over year (YOY) to $928.93 million, beating the $909.61 million analysts had modeled by roughly $19.3 million. Adjusted earnings per share came in at $4.31, topping the $3.99 consensus estimate and rising sharply from $3.23 a year earlier, a 33% increase.

On a GAAP basis, diluted earnings per share climbed to $4 from $2.86, while net income jumped 38% to $105.1 million from $76.1 million in the prior-year quarter. Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) rose roughly 26% to about $255.8 million.

The company's net revenue margin, a key profitability gauge for online lenders, expanded to 61% from 58% a year earlier.

Loan Growth With Improving Credit Quality

The second quarter was not unusual. It was the company's eighth consecutive quarter of adjusted earnings-per-share growth above 30%. Consolidated loan originations grew 27% YOY to roughly $2.3 billion, helping push ending receivables up 28% to a record $5.5 billion.

At the same time, credit quality kept improving even as the loan book expanded. Consolidated net charge-offs fell to 7.3% from 8.1% a year ago.

In turn, management raised full-year 2026 guidance to revenue growth of 20% to 25% and adjusted earnings-per-share growth of 30% to 35%.

Grasshopper Could Transform Enova

What has attracted significant attention recently is the broader strategic story surrounding its pending purchase of Grasshopper Bancorp, the parent of Grasshopper Bank. If completed, the roughly $369 million cash-and-stock deal would give Enova a national bank charter for the first time. With access to Grasshopper Bank's deposits, the move could lower Enova's funding costs and allow it to hold more loans on its balance sheet instead of relying on securitizations and credit facilities.

Management has told investors that the deal should be more than 25% accretive once synergies fully mature. However, the transaction still needs approval from the Office of the Comptroller of the Currency (OCC) and the Federal Reserve. Both companies expect it to close sometime in the second half of 2026.

Regulatory Approval Remains a Hurdle

Fed approval, more than the company’s balance sheet, is the lingering risk here. In May, it was reported that Senators Elizabeth Warren and Chris Van Hollen sent letters urging federal regulators to block the Grasshopper acquisition. They argued that, with a bank charter, Enova could originate loans nationwide at annual rates as high as 300% under looser state usury limits.

Because both the OCC and the Fed must approve the deal, the senators’ objections could carry weight despite recent regulatory leniency in similar matters. But if regulators delay or reject the deal, Enova could once again be viewed as a specialty lender rather than a future chartered bank.

Wall Street Remains Bullish

For now, though, Wall Street appears convinced that Enova’s future is bright. Of the nine analysts currently covering the stock, eight have placed a Buy rating on the company, and one has tagged it a Strong Buy. With a consensus Buy recommendation, Enova carries no Sell or Hold ratings at present.

The average 12-month price target of $247.83 gives the stock only moderate upside, signaling that much of the optimism may already be priced in. Among the ratings, the highest price target is $280 per share, while the lowest is $200.

Indeed, much of that value has been building for some time. Enova is up 44% year-to-date and 88% over the past year. Over the past five years, the stock has climbed well over 500%.

Stock Gains Raise the Valuation Bar

Based on these results, Enova's underlying business appears to be executing about as well as a specialty consumer and small-business lender can. Its revenue and profits are both climbing, credit quality is improving, and a possible bank charter could significantly lower funding costs.

Ironically, the risk is how well the stock has been performing. Shares are down nearly 15% after hitting highs in August. At some point, a prolonged run of this magnitude leaves less and less room for surprises. The fate of the Grasshopper deal also matters, perhaps even more than a single quarter’s earnings.

The fact is that every company carries some degree of risk. Whether Enova’s risks are weighty remains to be seen.